Aprea Therapeutics, Inc. (APRE)

Current Report Filed: 2026-04-01

Aprea Therapeutics has closed a $30 million private placement, providing additional capital to fund its ongoing operations and development programs.
The filing does not indicate any major changes in the company's leadership, material agreements, or financial performance, suggesting a routine business update.
Without additional context about the company's recent performance or pipeline, it is difficult to assess the long-term significance of this capital raise for Aprea Therapeutics' future prospects.

Insider Trading Filed: 2026-04-01

Insider Richard Peters acquired pre-funded warrants and common warrants to purchase a total of 247,830 shares of Aprea Therapeutics, Inc. (APRE) common stock at discounted prices in a private placement.
The pre-funded warrants are immediately exercisable, subject to a beneficial ownership limitation, while the common warrants will expire on the earlier of December 31, 2029 or 30 days after the pre-funded warrants are exercised.
The insider acquisition suggests Peters' confidence in Aprea Therapeutics' future prospects and could signal potential upside for the stock if the warrants are exercised.

Insider Trading Filed: 2026-04-01

The reporting person, John P. Hamill, who is the Senior VP, CFO, and Principal Financial and Accounting Officer of Aprea Therapeutics, Inc. (APRE), acquired pre-funded warrants and accompanying common warrants to purchase a total of 61,956 shares of the company's common stock on March 31, 2026.
The pre-funded warrants are immediately exercisable, subject to a beneficial ownership limitation of 4.99% of the company's outstanding shares or 9.99% of the company's voting power.
The common warrants are also immediately exercisable, subject to the same beneficial ownership limitation, and will expire on the earlier of December 31, 2029, or 30 days after the pre-funded warrants are exercised, proportional to the amount of such exercise.

Current Report Filed: 2026-03-30

Aprea Therapeutics raised approximately $30 million through a private placement of pre-funded warrants and common stock warrants, which provides additional funding to support the company's ongoing operations and drug development efforts.
The company granted the investors registration rights, requiring Aprea to file a registration statement to enable the resale of the shares underlying the warrants, improving the liquidity of these securities.
The warrants have customary terms, including limitations on ownership concentration, cashless exercise provisions, and lack of price-based anti-dilution protections, suggesting balanced terms for both the company and investors.

Current Report Filed: 2026-03-16

Aprea Therapeutics reported its Q4 2025 and full-year 2025 financial results, providing an update on its operations during the period.
The company updated its corporate presentation slide deck, which may provide additional insights into its business strategy and development pipeline.
As an 8-K filing, this report discloses material information that may be of interest to investors, such as financial performance and corporate developments.

Annual Report Filed: 2026-03-16

Aprea Therapeutics, Inc. reported a significant increase in revenue and earnings in fiscal year 2025 compared to the prior year.
The company completed two At-the-Market offerings in 2024 and 2025, raising additional capital to fund ongoing research and development activities.
Aprea Therapeutics announced a private placement in January 2026 with certain investors, providing additional funding to support the business.

Current Report Filed: 2026-01-29

Aprea Therapeutics has raised approximately $5.6 million in a private placement of common stock and warrants, providing additional capital to fund the company's operations.
The company has granted the investors registration rights, requiring Aprea to file a registration statement within 60 days to allow for the resale of the shares issued in the private placement.
The warrants issued in the transaction have a 2-year exercise period and contain favorable terms, including the ability to exercise on a cashless basis and no price reset provisions.

Current Report Filed: 2026-01-23

Aprea Therapeutics has received a notice from Nasdaq that its stock price has fallen below the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market.
The company has been given a 180-day compliance period to regain compliance by having a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days.
If the company fails to regain compliance within the initial 180-day period, it may be eligible for a second 180-day compliance period, but if it is unable to comply by the end of the extended period, its stock may be subject to delisting.

Current Report Filed: 2026-01-09

Aprea Therapeutics has updated its corporate presentation slide deck, which may provide investors with new information about the company's strategic direction and key developments.
The filing does not indicate any major events or changes, suggesting this is a routine update to the company's investor materials.
Investors should review the updated presentation for any significant updates on the company's pipeline, financial performance, or other material information.

Important Information